Imipenem | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Imipenem
US Patents

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Imipenem

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

27 API Suppliers, 16 USDMF, 3 CEP/COS, 2 JDMF, 2 EU WC, 3 KDMF, 3 NDC API, 8 Listed Suppliers, $ API Reference Price

27 API Suppliers
16 USDMF
3 CEP/COS
2 JDMF
2 EU WC
3 KDMF
3 NDC API
8 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

INTERMEDIATES

1 Intermediates Suppliers

1 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

48 FDF Dossiers, 13 FDA Orange Book, 10 Europe, 4 Canada, 9 South Africa, 12 Listed Dossiers

48 FDF Dossiers
13 FDA Orange Book
10 Europe
4 Canada
9 South Africa
12 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

POWDER;INTRAVENOUS - EQ 250MG BASE/VIAL;250MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, POWDER;INTRAVENOUS - EQ 500MG BASE/VIAL;500MG/VIAL

POWDER;INTRAVENOUS - EQ 250MG BASE/VIAL;250MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
POWDER;INTRAVENOUS - EQ 500MG BASE/VIAL;500MG/VIAL

RELATED EXCIPIENT COMPANIES

1 SPI Pharma

1 SPI Pharma

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 20 NEWS #PharmaBuzz

1 DATA COMPILATION #PharmaFlow
20 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 10 Finished Drug Prices, 10 Annual Reports

1 US Medicaid Prescriptions
10 Finished Drug Prices
10 Annual Reports

MARKET PLACE

14 APIs, 4 FDF Dossiers

14 APIs
4 FDF Dossiers

PATENTS & EXCLUSIVITIES

3 US Patents, 2 US Exclusivities

3 US Patents
2 US Exclusivities

REF. STANDARDS & IMPURITIES

1 EDQM, 1 USP, 1 Others

1 EDQM
1 USP
1 Others

$ API Ref.Price (USD/KG) : 1,493 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

3 All

01 3MSD MERCK CO

filter Patent Number Reset all filters

3 All

01 38487093

filter API Patent Reset all filters

3 All

01 3Y

filter FDF Patent Reset all filters

3 All

01 3Y

filter Expiration Date Reset all filters

3 All

01 32033-03-21

Product Main Page

01

MSD MERCK CO

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

2024 ACI Convention

Not Confirmed

MSD MERCK CO

2024 ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-03-21

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

US Patent Number : 8487093

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 212819

Patent Use Code : U-2587

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-03-21

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

MSD MERCK CO

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

2024 ACI Convention

Not Confirmed

MSD MERCK CO

2024 ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-03-21

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

US Patent Number : 8487093

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 212819

Patent Use Code : U-2840

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-03-21

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

MSD MERCK CO

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

2024 ACI Convention

Not Confirmed

MSD MERCK CO

2024 ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-03-21

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

US Patent Number : 8487093

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 212819

Patent Use Code : U-2586

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2033-03-21

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?